Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02687867 · ClinicalTrials.gov registry record
Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 56,039
- Enrollment target
NCT02687867: Completed study, sponsored by Bayer.
NCT02687867 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 56,039 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02687867 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 56,039 participants
- Enrollment target
Study Summary
To obtain a better understanding on the comparative effectiveness of dabigatran versus Vitamin K antagonist (VKA) for stroke prevention in patients with Non-valvular atrial fibrillation (NVAF) in a real-life setting.
Interventions
- DRUG Dabigatran (Pradaxa)
- DRUG Vitamin K antagonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56,039 participants |
| Start Date | 2016-02-12 |
| Est. Completion | 2016-03-01 |
What the finished NCT02687867 record still lists
NCT02687867 is an observational study that tracks outcomes without assigning an intervention. Its 56,039 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Dabigatran (Pradaxa) is the first listed.
NCT02687867 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02687867 about?
NCT02687867 is a clinical study titled "Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist". To obtain a better understanding on the comparative effectiveness of dabigatran versus Vitamin K antagonist (VKA) for stroke prevention in patients with Non-valvular atrial fibrillation (NVAF) in a real-life setting.
What is the current status of trial NCT02687867?
This trial is currently completed. The enrollment target is 56,039 participants. The study started on 2016-02-12. Estimated completion is 2016-03-01.
What interventions are being tested in trial NCT02687867?
The interventions under investigation include: Dabigatran (Pradaxa) (DRUG), Vitamin K antagonist (DRUG).
Who is sponsoring clinical trial NCT02687867?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07224243 · 54,000 participants · NA
Impact of Intraoperative Oxygenation Practices on Patient Outcomes
- NCT05975671 · 52,500 participants · NA
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
- NCT06355934 · 52,121 participants
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
- NCT00785525 · 60,000 participants · Phase 3
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI